Effect of D-glucitol-hexanicotinate on platelet aggregability in patients with coronary heart disease.

Abstract

D-glucitol-hexanicotinate (sorbinicate) was administered at a daily dose of 1.6 mg to 16 male patients who had survived myocardial infarction. Platelet aggregation induced by collagen (5 micrograms/ml), by ADP (2, 1.2, 0.8, and 0.4 X 10(-6)M), and by epinephrine (1 and 0.5 X 10(-6)M) was significantly decreased after 3 months of therapy. In a group of 13 comparable patients, who did not receive sorbinicate, platelet aggregation induced by ADP (1.2, 0.8, and 0.4 X 10(-6)M) and by epinephrine (1 X 10(-5)M and 1 X 10(-6)M) was significantly increased 3 months after entry into the study. Sorbinicate has effective lipid-lowering activity; the combination of hypolipidemic and anti-aggregating properties may prove important in primary and secondary prevention of atherosclerotic disease.

• Authors: D Sommariva, F E Panigo, L Rovelli, D Bonfiglioli, M Garimoldi, A Cialfi, R Gandini, A Fasoli
• Journal: International journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 22 Issue 5 Pg. 265-8 (May 1984) ISSN: 0174-4879 [Print] Germany
• PMID: 6746150 (Publication Type: Journal Article)

Chemical References

• Hypolipidemic Agents
• Nicotinic Acids
• glucitol hexanicotinate
• Sorbitol
• Adenosine Diphosphate
• Epinephrine

Topics

• Adenosine Diphosphate (pharmacology)
• Adult
• Coronary Disease (blood)
• Epinephrine (pharmacology)
• Humans
• Hypolipidemic Agents (pharmacology)
• Male
• Middle Aged
• Myocardial Infarction (blood)
• Nicotinic Acids (pharmacology)
• Platelet Aggregation (drug effects)
• Sorbitol (analogs & derivatives, pharmacology)